Effect of rifampin with bio-enhancer in the treatment of newly diagnosed sputum positive pulmonary tuberculosis patients: A double-center study
Objective: To compare a fixed-dose combination (FDC) of Rifampicin 450 mg, Isoniazid 300 mg, Pyrazinamide 1500 mg and Ethambutol 800 mg (usual care group) and regimen of Rifampicin 200 mg, Isoniazid 300 mg and piperine 10 mg along with Pyrazinamide 1500 mg and Ethambutol 800 mg (intervention care gr...
Main Authors: | A.D. Nageswari, M.G. Rajanandh, M.K.R.A. Uday, R.J. Nasreen, R.R. Pujitha, G. Prathiksha |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-08-01
|
Series: | Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405579418300445 |
Similar Items
-
Direct detection of Mycobacterium tuberculosis rifampin resistance in bio-safe stained sputum smears.
by: Surabhi Lavania, et al.
Published: (2017-01-01) -
Periostin - A Novel Systemic Biomarker for Eosinophilic Airway Inflammation: A Case Control Study
by: Viswanathan EMPRM, et al.
Published: (2016-02-01) -
Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA
by: Scott K. Heysell, et al.
Published: (2013-01-01) -
Assessment of sputum smear-positive but culture-negative results among newly diagnosed pulmonary tuberculosis patients in Tanzania
by: Mnyambwa NP, et al.
Published: (2017-07-01) -
Evaluation of Xpert® Mycobacterium tuberculosis/rifampin in sputum-smear negative and sputum-scarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid
by: Nikhil C Gowda, et al.
Published: (2018-01-01)